Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. Distinct Autoimmune Anti-α-Synuclein Antibody Patterns in Multiple System Atrophy and Parkinson’s Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Peptide Super-Agonist Enhances T-Cell Responses to Melanoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Complement Nomenclature-Deconvoluted

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. The real-world outcome of metastatic melanoma: Unknown primary vs. known cutaneous

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope

    Research output: Contribution to journalReviewResearchpeer-review

  3. Chimeric antigen receptor-T-cellebehandling

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Terapeutisk cancervaccination mod hæmatologisk cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Peptides vaccination is an interesting approach to activate T-cells toward desired antigens in hematological malignancies. In addition to classical tumor associated antigens, such as cancer testis antigens, new potential targets for peptide vaccination comprise neo-antigens including JAK2 and CALR mutations, and antigens from immune regulatory proteins in the tumor microenvironment such as programmed death 1 ligands (PD-L1 and PD-L2). Immunosuppressive defenses of tumors are an important challenge to overcome and the T cell suppressive ligands PD-L1 and PD-L2 are often present in tumor microenvironments. Thus, PD-L1 and PD-L2 are interesting targets for peptide vaccines in diseases where the tumor microenvironment is known to play an essential role such as multiple myeloma and follicular lymphoma. In myelodysplastic syndromes the drug azacitidine re-exposes tumor associated antigens, why vaccination with related peptides would be an interesting addition. In myeloproliferative neoplasms the JAK2 and CALR mutations has proven to be immunogenic neo-antigens and thus possible targets for peptide vaccination. In this mini review we summarize the basis for these novel approaches, which has led to the initiation of clinical trials with various peptide vaccines in myelodysplastic syndromes, myeloproliferative neoplasms, multiple myeloma, and follicular lymphoma.

Original languageEnglish
JournalFrontiers in Immunology
Volume9
Pages (from-to)2264
ISSN1664-3224
DOIs
Publication statusPublished - 2018

ID: 55680616